The government and the MCI dither on a proposed course to provide better primary health care in villages. On February 27, the Delhi High Court slapped contempt notices on the Union Health Secretary and the Chairperson of the Medical Council of India (MCI) for their non-compliance with its order of November 10, 2010, to initiate measures to introduce a “Bachelor of Rural Health Care (BRHC)” course of three and a half...
More »SEARCH RESULT
Total Matching Records found : 97
More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh
-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...
More »How PH Kurien took on global patents system to make very costly drug affordable for poor-Arvind Panagariya
It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever Compulsory licence in India for the manufacture of a drug still under patent....
More »Bayer demands withdrawal of Natco Pharma's Compulsory licence-Khomba Singh
German drugmaker Bayer AG has demanded the withdrawal of the country's first Compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...
More »Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »
